SCHEMBL5459209

SCHEMBL5459209

COc1ccc(Cc2ccc(S(=O)(=O)c3cc4c(cc3N(C)C)CCN(C)CC4)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 3/20 0.43
DRD5 P21918 3/20 0.43
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LTA4H P09960 1/20 0.42
PKM P14618 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
CNR2 P34972 2/20 0.40
DRD4 P21917 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TYMS P04818 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448126 0.91 LTA4H (0.47) DRD1DRD5DRD2DRD3ALDH1A1
SCHEMBL5467071 0.89 LMNA (0.43) GAAHTR2AHTR2CLTA4HPKM
SCHEMBL5452773 0.88 USP2 (0.42) DRD2DRD3HTR2AHTR2CUSP2
SCHEMBL14411990 0.88 HTR6 (0.43) DRD2DRD3HTR2AHTR2CLTA4H
SCHEMBL5453002 0.88 USP2 (0.42) DRD2DRD3ALDH1A1GAAHTR2A
SCHEMBL5453022 0.88 HTR2A (0.46) ALDH1A1HTR2ASLC6A4SLC6A3USP2
SCHEMBL5462456 0.87 USP2 (0.41) DRD1DRD5DRD2DRD3ALDH1A1
SCHEMBL5445721 0.87 USP2 (0.41) DRD2DRD3HTR2AHTR2CSIGMAR1
SCHEMBL5452896 0.87 HTR2C (0.42) DRD2DRD3ALDH1A1HTR2AHTR2C
SCHEMBL5457597 0.85 USP2 (0.40) DRD2DRD3HTR2AHTR2CSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 DRD1 21/4885DRD5 85/4885DRD2 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.